| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cytokinetics, Incorporated (CYTK) has 14 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. CYTK is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 400.3K | $31.69M | - | |
| VP | 141.5K | $11.21M | - | |
| Other | 87.3K | $6.91M | - | |
| VP | 73.6K | $5.82M | -15,000 | |
| CFO | 70.1K | $5.55M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sale+OE | 100 | $45.00 | $4,500.00 | -0.3% | -25.2% | +35.4% | |
| Mar 13, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 26,771 | $43.62 | $1,167,751.02 | -41.5% | -25.4% | +35.3% | |
| Mar 6, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 3,341 | $43.27 | $144,565.07 | -4.9% | -25.1% | +39.6% | |
| Mar 6, 2025 | Malik Fady Ibraham55 | EVP Research &Development | Sell | 8,228 | $43.27 | $356,025.56 | -7.2% | -25.1% | +39.6% | |
| Mar 6, 2025 | Blum Robert I51 | President &CEO | Sell | 16,970 | $43.44 | $737,176.80 | -4.5% | -25.1% | +39.6% | |
| Mar 5, 2025 | Blum Robert I51 | President &CEO | Sell | 25,000 | $43.23 | $1,080,750.00 | -6.2% | -27.1% | +41.7% | |
| Mar 4, 2025 | Malik Fady Ibraham55 | EVP Research &Development | Sale+OE | 2,000 | $42.50 | $85,000.00 | -1.7% | -28.6% | +42.5% | |
| Mar 4, 2025 | Harrington Robert Arthur51 | Director | Sell | 900 | $42.50 | $38,250.00 | -5.6% | -28.6% | +42.5% | |
| Mar 3, 2025 | Malik Fady Ibraham55 | EVP Research &Development | Sell | 2,449 | $42.88 | $105,013.12 | -2.1% | -27.2% | +41.5% | |
| Mar 3, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,114 | $42.88 | $47,768.32 | -1.6% | -27.2% | +41.5% |